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Multicomponent Reactions
Efficient Diastereoselective Three-Component Synthesis of
Pipecolic Amides
Gydo van der Heijden,[a] Timo B. van Schaik,[a] Valentinos Mouarrawis,[a]
Martin J. M. de Wit,[a] Christophe M. L. Vande Velde,[b] Eelco Ruijter,*[a] and
Romano V. A. Orru*[a]
Abstract: An efficient Ugi-type three-component reaction
(U-3CR) for the synthesis of pipecolic amides is reported. The
U-3CR between electronically diverse isocyanides, carboxylic
acids and 4-substituted Δ1-piperideines proceeds in a highly
diastereoselective fashion. The Δ1-piperideines are obtained by
NCS-mediated oxidation of the corresponding 4-substituted
Introduction
In the past decades, isocyanide-based multicomponent reac-
tions (IMCRs) have proven their value as useful tools for the
generation of structurally diverse compound libraries.[1–3] The
products resulting from these reactions generally feature con-
siderable molecular complexity, as well as one or more new
stereocenters. An important advance in the field of IMCRs is the
development of methods to gain stereocontrol with the use of
cleverly designed (organo)catalysts.[4–8] For one of the most
widely used IMCRs, the Ugi four-component reaction (U-4CR),
no general catalytic method was available until very recently.[9]
An alternative approach to control the stereochemistry of the
Ugi reaction is to use chiral starting materials. Unfortunately,
the diastereoselectivity in Ugi reactions is generally very poor,
especially for chiral isocyanides and carboxylic acids.[10] More-
over, aldehyde inputs have similar problems with the additional
disadvantage that the α-carbon easily undergoes racemization
(or epimerization).[11] However, the combination of two differ-
ent functional groups in a single (chiral) reactant provides much
better stereocontrol. This has especially been demonstrated in
the formation of (macro)cycles.[12–14] In addition, chiral amine
and imine inputs also typically show reasonable induction in
the U-4CR.[15–19]
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piperidines, which in turn are generated by an efficient two-
step procedure involving the alkylation of 4-picoline and subse-
quent catalytic hydrogenation of the pyridine ring. We demon-
strate the utility of this U-3CR, in combination with the converti-
ble isocyanide 2-bromo-6-isocyanopyridine, in the synthesis of
the anticoagulant argatroban.
In the past, we reported a highly diastereoselective Ugi
three-component reaction (U-3CR) using optically pure 3,4-cis-
substituted bicyclic 1-pyrrolines for the synthesis of prolyl pept-
ides.[15] The diastereoselectivity arises from the steric bulk
present in the 1-pyrroline skeleton. This methodology provides
access to medicinally relevant prolyl peptides, including the
hepatitis C virus NS3 protease inhibitor telaprevir.[16] Prolyl
peptides are desirable building blocks for medicinal chemistry
due to the high occurrence of proline in proteins and oligo-
peptides. Moreover, amides of the structural homologs of
proline, pipecolic acid, are common structural motifs in bioac-
tive compounds.[17–19] Especially 4-substituted pipecolic acid
derivatives are an important class of compounds. A large subset
of this class consists of bioactive 2,4-cis-substituted pipecolic
amides or acids, such as the potent HIV inhibitor palanivir[20]
and the NMDA antagonist selfotel[21,22] (Scheme 1A, 1 and 2,
respectively). Additionally, 2,4-trans-pipecolic acid derivatives
are key motifs in for example antitumor agents and the throm-
bin inhibitor argatroban (3).[23]
According to the literature Δ1-piperideines (5) as well as
other cyclic imines are good substrates for IMCR chemistry, e.g.
for the synthesis of pipecolic acids[24] and acyldepsipeptide
antibiotics.[25,26] Furthermore, El Kaïm and co-workers have
shown that 4-benzyl Δ1-piperideine is a good substrate for the
Ugi–Smiles reaction.[27] Since 2,4-pipecolic amides are highly
valuable structural motifs, we became interested in the general-
ity of Δ1-piperideines (5) as inputs for the U-3CR (Scheme 1B).
Moreover, we envisioned a possible application in the synthesis
of argatroban (3). Argatroban is an important therapeutic anti-
coagulant that directly inhibits the thrombin enzyme, which is
responsible for the blood clotting in thrombosis.[28] The drug is
mainly administered to patients with a history of coronary ar-
tery disease (CAD) or stroke, when the conventional antithrom-
botic drug heparin results in heparin-induced thrombocytope-
nia (HIT) or platelet deficiency.[29] Scheme 1C depicts our retro-
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Scheme 1. A: Bioactive 4-substituted pipecolic acid derivatives. B: our synthetic approach toward 2,4-disubtituted pipecolic amides (6). C: Retrosynthetic plan
for argatroban (3) using the U-3CR approach and convertible isocyanide 7.
synthetic plan for argatroban, which requires straightforward
access to Δ1-piperideines 5 and high diastereoselectivity in the
U-3CR for pipecolic amides 6. This, in combination with the use
of our universal convertible isocyanide, 2-bromo-6-isocyanopyr-
idine (7),[30] would result in a highly convergent and very short
synthesis of argatroban (3).
Results and Discussion
Since only a handful of different 4-substituted piperidines (4) is
commercially available, we decided to prepare a considerable
set of them ourselves. Initially, we tried to synthesize them via a
Wittig reaction of N-Cbz piperidone and different alkyltriphenyl-
phosphonium halides followed by catalytic hydrogenation of
the resulting alkenes. However, the desired 4-substituted piper-
idines were obtained in rather modest overall yields (>45 %).
We therefore developed an alternative strategy involving lithi-
ation and alkylation of 4-picoline (10)[31,32] with different alkyl
bromides followed by catalytic hydrogenation of the resulting
Eur. J. Org. Chem. 2019, 5313–5325 www.eurjoc.org © 2019 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim5314
4-alkyl-pyridines 11 over PtO2 (Scheme 2).[33,34] The alkylation
proceeded very efficiently with primary and secondary alkyl
bromides to produce the corresponding 4-alkyl pyridines 11 in
Scheme 2. Synthesis of 4-alkylpiperidines 4a–j from 4-picoline 10.[a] Isolated
yields over 2 steps.[b] Lower overall yield is due to less efficient double alkyl-
ation, the hydrogenation proceeds in all cases in near quantitative yield.[c] 4-
phenylpyridine could also be used as the starting material in the PtO2-reduc-
tion step generating 4h in 94 % isolated yield.
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high yields. The double alkylation with 1,3-dibromopropane
and 1,4-dibromobutane using two equivalents of LDA proved
successful as well, directly providing the corresponding 4-cyclo-
pentyl- and 4-cyclohexylpyridines. The subsequent hydrogen-
ation of 11 was performed with PtO2 as catalyst in the presence
of HCl to obtain the desired 4a–h as odorless HCl salts (a signifi-
cant advantage compared to the foul smelling free base liquids
resulting from the Wittig strategy). Reduction of pyridines is
generally performed under elevated hydrogen pressure and re-
action temperature, however we discovered that atmospheric
hydrogen pressure at room temperature worked equally effi-
cient to provide piperidinium salts 4a–h in near quantitative
yields. Interestingly, the use of 4-phenylpyridine as the starting
material for the hydrogenation also provided 4-cyclohexyl
piperidine 4h in similar yield through reduction of the conju-
gated phenyl ring.[35]
With the 4-alkylpiperidines 4 in hand we synthesized the
corresponding (racemic) Δ1-piperideines 5 by NCS-mediated
chlorination followed by HCl elimination using ethanolic KOH
(Scheme 3).[36] 1H NMR analysis indicated that the imines were
not stable and rapidly formed diastereomeric mixtures of tri-
mers (12), which made it difficult to assess the kinetics of the
process. To validate if these trimers would still be reactive in-
puts for the U-3CR, we reacted the obtained mixtures of race-
mic imines 5 and trimers 12 with a set of different isocyanides
(13) and carboxylic acids (14, Scheme 4).
Scheme 3. Synthesis of racemic Δ1-piperideines 5 and formation of trimers
12.
To our delight, the corresponding pipecolic amides 6 were
obtained in generally excellent yields, indicating that the trime-
rization is reversible under the reaction conditions. In addition,
the pipecolic amides 6 were obtained as single diastereomers,
regardless of the size of the alkyl group on the piperidine ring.
X-ray crystallographic analysis of compound 6q confirmed the
expected 2,4-trans-configuration of the pipecolic amides (see
Scheme 4 and the Supporting Information). All other pipecolic
amides 6 were assigned the same 2,4-trans-configuration by
similarity and comparison of 1H NMR coupling constants.
The scope of the reaction is very broad in terms of both the
isocyanide and carboxylic acid inputs. Both primary, secondary
and tertiary aliphatic isocyanides yield the corresponding
pipecolic amides 6 in decent isolated yields. This includes iso-
cyanides bearing a strongly electron withdrawing α-ester moi-
ety (the α-acidic methyl isocyanoacetate) that give the pipecolic
amide products 6e and 6m, albeit in slightly lower yields (69 %
and 62 %, respectively) compared to the other isocyanide in-
puts (76–97 %). The carboxylic acid component can be varied
widely as well. We employed acetic and pivalic acid giving the
corresponding pipecolic amides in good to excellent yields.
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Scheme 4. The scope of the diastereoselective U-3CR towards pipecolic
amides 6 and the crystal X-ray structure of compound 6q with displacement
ellipsoids drawn at 50 % probability level.
Even carboxylic acids functionalized with a double bond result
efficiently in the pipecolic amides 6f, 6j, and 6p. Also, carboxylic
acids with R2 = aromatic (Ph) or benzylic (PMB) are well toler-
ated in our three-component reaction. The more congested pi-
valic acid proved to be an advantageous input for NMR analysis.
Most U-3CR products appear as rotamers in the NMR spectra
due to hindered rotation of the tertiary amide bond. The steric
bulk of the tBu group strongly disfavors one of the possible
amide conformations, which greatly simplifies the NMR analysis.
The diastereoselectivity of the U-3CR is determined by the
attack of the isocyanide on the charged iminium species. Al-
though nucleophilic attack of the isocyanide from the top face
is less hindered due the neighboring equatorial H-atom, this
can hardly account for the complete trans selectivity observed.
However, the observed selectivity can be satisfyingly rational-
ized by the Fürst-Plattner rules (Scheme 5).[37] The initial
Δ1-piperideines will, after protonation by the carboxylic acid,
most likely adopt the preferred half-chair conformation 5′ with
the alkyl substituent positioned pseudo-equatorially.
Nucleophilic attack of the isocyanide (13) may then come
from the bottom face (equatorial attack, in red), leading to an
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Scheme 5. The proposed mechanism of isocyanide attack on the protonated Δ1-piperideines 5′ leading to diastereoselective formation of trans-pipecolic
amides 6.
disfavored twist-boat conformation I, or from the top face (axial
attack, in green), leading directly to a more favorable chair con-
formation (II). Consequently, the kinetic barrier for an axial
attack is much lower than for an equatorial attack, providing
exclusively the trans-product.[38,39]
With the broad scope of the U-3CR and selective formation
of the 2,4-trans configured pipecolic amides 6 in hand, we envi-
sioned a strategy for the total synthesis of argatroban
(Scheme 1C, 3). Argatroban (3) contains four stereocenters, of
which the stereochemistry of the 2,4-disubstitued pipecolic
amide and the arginine moiety are defined. Two rather similar
approaches for the synthesis of 3 have been reported.[40,41] The
first approach, developed by the Mitsubishi corporation, utilizes
optically pure ethyl (2R,4R)-4-methyl-piperidine-2-carboxylate
(Scheme 6A, 17) obtained from 15 or 16. After optical resolu-
tion by crystallization with l-tartaric acid, a lengthy linear se-
quence of standard protection/deprotection and peptide cou-
pling reactions gave argatroban (3).[40] Later, Cossy and Bellotti
reported an improved synthesis following a similar strategy
(Scheme 6B).[41] To avoid the troublesome enantioselective syn-
thesis of pipecolic ester 17 they used the readily accessible ra-
cemic pipecolic ester rac-18, which was prepared by α-lithiation
of N-Boc-4-methylpiperidine. The resulting 2-lithiated species
was quenched with benzyl chloroformate to obtain the corre-
sponding amino ester with high diastereoselectivity in favor of
the trans-diastereomer (up to 95:5).[42] Subsequent coupling of
18 to Nω-nitro-l-arginine and separation of the diastereomers
by flash chromatography gave optically pure 19. Finally,
the synthesis of 3 was completed in a similar fashion as the
Mitsubishi synthesis. It should be noted that commercial
argatroban (3) is administered as a 64:36 mixture of the 21-(R)-
and 21-(S) epimers (at the 3-methyltetrahydroquinoline moiety),
because the C21 stereocenter is generated in a poorly selective
final catalytic hydrogenation step of the quinoline ring
(Scheme 6C).[43]
Our retrosynthetic analysis (Scheme 1C) shows that next to
Δ1-piperideine 5a, the functionalized and protected arginine
derivative 8 is required. Furthermore, our U-3CR strategy takes
advantage of a convertible isocyanide 7 as a starting material
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Scheme 6. A: The Mitsubishi synthesis of argatroban (3).[40] B: The Cossy and
Belotti synthesis of argatroban (3).[41] C: Commercial C21 hydrogenation of
the quinolone ring.[43]
resulting in the secondary amide 9 that should undergo selec-
tive hydrolysis to the corresponding carboxylic acid. Recently,
we developed 2-bromo-6-isocyanopyridine (7) as a universal
convertible isocyanide for selective post-transformations of Ugi
and Passerini products under mild acidic or alkaline condi-
tions.[30]
Piperideine 5a was obtained from commercial 16 by the
NCS-mediated chlorination followed by HCl elimination de-
scribed in Scheme 3. For the NO2-protected quinolyl sulfon-
amide 8a (PG = NO2) we initially envisioned to use (like Cossy
and Belotti) Nω-nitro-l-arginine as the functionalized carboxylic
acid input for the U-3CR. This should have several advantages.
Firstly, the nitro group is much smaller than most other protec-
tion groups, improving the overall atom economy. Secondly,
the nitro group is one of the strongest electron-withdrawing
groups, which completely deactivates the guanidine, resulting
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Scheme 7. Synthesis of argatroban using the diastereoselective U-3CR for pipecolic amides.
in higher yields in the U-3CR. Finally, the nitro group can be
removed in the final reaction step simultaneously with the re-
duction of the quinolone ring. An initial test of the U-3CR/hy-
drolysis route using 5a, Nω-nitro-l-arginine and our convertible
isocyanide 7 indicated that the nitroguanidine group of 9a
(PG = NO2) degrades during the hydrolysis step, giving the cor-
responding primary amine or urea derivatives (as determined
by 1H NMR and HPLC-MS analysis). Therefore, we favored the
double Cbz, mono Boc protected arginine 21 as input
(Scheme 7), which can also be removed in the final hydrogen-
ation reaction. Thus, the Boc group of 21 was removed by treat-
ment with TFA and the resulting amine was sulfonylated with
3-methyl-8-quinolinesulfonyl chloride (22) in the presence of
DIPEA to furnish double Cbz-protected carboxylic acid 8b in
nearly quantitative yield. Our diastereoselective three-compo-
nent pipecolic amide synthesis using 8b in combination with
convertible isocyanide 7 and racemic imine 5a[44] gave Cbz-
protected U-3CR product 9b in 65 % yield. This nicely demon-
strates that our three-component reaction towards pipecolic
amides is really robust tolerating even highly functionalized
carboxylic acids as well as the less nucleophilic heteroaromatic
isocyanides as inputs. The activated amide of 9b, resulting from
the 2-bromo-6-isocyanopyridine 7, was hydrolyzed with aque-
ous NaOH at elevated temperature. Interestingly, the Cbz
groups appear sensitive to these reaction conditions, resulting
in the quantitative removal of one of the Cbz groups and partial
Eur. J. Org. Chem. 2019, 5313–5325 www.eurjoc.org © 2019 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim5317
removal of the other. Finally, the quinolone ring was reduced,
and the remaining Cbz-group was removed by catalytic hyd-
rogenation (H2, Pd/C) to afford argatroban (3) in 83 % yield as
a mixture of two diastereoisomers. In order to obtain the (L,R,R)-
diastereoisomer of 3, the 1:1 mixture of the (L,S,S)- and (L,R,R)
Ugi diastereomers 9b was separated by supercritical fluid chro-
matography (SFC).[45] The desired diastereomer was converted
under similar conditions to obtain (L,R,R)-3 as a 36:64 mixture
of epimers at the quinolone C21 stereocenter.[46]
Conclusions
In conclusion, we have developed an efficient and highly dia-
stereoselective U-3CR with Δ1-piperideines as versatile inputs.
The reaction tolerates chemically diverse isocyanides and carb-
oxylic acids leading to a wide variety of medicinally interesting
pipecolic amides. The desired 4-substituted Δ1-piperideines
were made by a simple chemical oxidation of the correspond-
ing piperidines. These piperidines were synthesized by an alkyl-
ation of 4-picoline followed by hydrogenation of the pyridine
ring with hydrogen and catalytic PtO2 in the presence of HCl.
As a demonstration of the potential of the U-3CR, we used our
methodology in combination with our recently developed con-
vertible isocyanide 2-bromo-6-isocyanopyridine for a very short
synthesis of the anticoagulant argatroban (3).
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Experimental Section
General Remarks: Unless stated otherwise, all solvents and com-
mercially available reagents were used as purchased. All reactions
were performed under air, unless stated otherwise. Infrared (IR)
spectra were recorded neat using a Shimadzu FTIR-8400s spectro-
photometer and wavelengths are reported in cm–1. Nuclear mag-
netic resonance (NMR) spectra were recorded on a Bruker Avance
500 (125.78 MHz for 13C) or Bruker Avance 400 (100.62 MHz for 13C)
using the residual solvent as internal (1H: δ 7.26 ppm, 13C{1H}: δ
77.00 ppm for CDCl3, 1H: δ 2.50 ppm, 13C{1H}: δ 39.52 ppm for
[D6]DMSO and 1H: δ 3.31 ppm, 13C{1H}: δ 49.00 ppm for [D4]MeOD).
Chemical shifts (δ) are given in ppm and coupling constants (J) are
quoted in Hertz (Hz). Resonances are described as s (singlet), d
(doublet), t (triplet), q (quartet), bs (broad signal) and m (multiplet)
or combinations thereof. Chiral HPLC was recorded using a LC10VP
with a SCL-10A VP system controller, LC-10AT VP liquid chromato-
graph, SPD-M10A VP diode array detector and CTO-10AC VP col-
umn oven from Shimadzu. Data was processed using Shimadzu
Labsolutions. Semi-preparative reverse phase HPLC was recorded
using a LC20 with a CBM-20A communications bus module,
LC-20AT liquid chromatograph, SPD-M20A diode array detector, SIL-
20A auto sampler, CTO-20AC column oven and a FRC-10A fraction
collector from Shimadzu. Melting points were recorded on a Büchi
M-565 melting point apparatus and are uncorrected. Electrospray
Ionization (ESI) high-resolution mass spectrometry was carried out
using a Bruker micrOTOF-Q instrument in positive ion mode (capil-
lary potential of 4500 V). Flash chromatography was performed on
Silicycle Silia-P Flash Silica Gel (particle size 40–63 μm, pore diame-
ter 60 Å) using the indicated eluent. Thin Layer Chromatography
(TLC) was performed using TLC plates from Merck (SiO2, Kieselgel
60 F254 neutral, on aluminium with fluorescence indicator) and
compounds were visualized by UV detection (254 nm) and KMnO4
stain. Protected arginine 21 (Boc-Arg(Cbz)2-OH), 3-methylquinoline-
8-sulfonyl chloride (22), 4-methylpiperidine (16), 4-phenylpiperidine
as well as pyridines 11a and 11e are commercially available and
were used as purchased.
Synthesis of 4-Substituted Piperidinium Salts (4)
General Procedure I. Synthesis of 4-Alkylpyridines (11): A flame
dried three-neck round-bottomed flask under N2 atmosphere was
charged with a solution of diisopropylamine (5.0 mL, 35.7 mmol,
1.55 equiv.) in anhydrous THF (100 mL). The reaction mixture was
cooled to –78 °C and a solution of n-butyllithium (1.6 M in hexanes,
21.6 mL, 34.5 mmol, 1.5 equiv.) was added dropwise. After 10 min,
the solution was warmed to 0 °C and stirred for another 20 min.
The solution was cooled again to –78 °C and 4-picoline (2.24 mL,
23 mmol, 1.0 equiv.) in anhydrous THF (15 mL) was added dropwise.
The resulting mixture stirred for 1 h resulting in a dark red solution.
Then the alkyl bromide (23 mmol, 1.0 equiv.) in anhydrous THF
(10 mL) was added dropwise at –78 °C. After stirring for 1 h, the
temperature was warmed to room temperature and stirred over-
night. The reaction mixture was quenched with saturated
NH4Cl(aq.) (50 mL). The layers were separated and the water layer
was extracted with EtOAc (3 ×). The organic layers were combined,
washed with brine, dried with anhydrous Na2SO4 and concentrated
under reduced pressure. The crude product was purified by flash
column chromatography providing the alkylpyridines as slightly yel-
low liquids.
General Procedure II: Synthesis of 4-Cycloalkylpyridines (11g
and 11h): A flame dried three-neck round-bottomed flask under
N2 atmosphere was charged with a solution of diisopropylamine
(10.0 mL, 71.3 mmol, 3.1 equiv.) in anhydrous THF (100 mL). The
reaction mixture was cooled to –78 °C and a solution of n-butyl-
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lithium (2.5 M in THF, 27.6 mL, 69.0 mmol, 3.0 equiv.) was added
dropwise. After 10 min, the solution was warmed to 0 °C and stirred
for another 20 min. The solution was cooled to –78 °C and 4-
picoline (2.24 mL, 23 mmol, 1.0 equiv.) in anhydrous THF (15 mL)
was added dropwise. The resulting mixture was stirred for 1 h re-
sulting in a dark red solution. Then the dibromoalkane (23 mmol, 1
equiv.) in anhydrous THF (10 mL) was added drop wise at –78 °C.
After stirring for 1 h, the temperature was warmed to room temper-
ature and the resulting mixture stirred overnight. The reaction mix-
ture was quenched with saturated NH4Cl(aq.) (50 mL). The layers
were separated and the water layer was extracted with EtOAc (3 ×).
The organic layers were combined, washed with brine, dried with
anhydrous Na2SO4 and concentrated under reduced pressure. The
crude product was purified by flash column chromatography pro-
viding the cycloalkylpyridines.
General Procedure III: Synthesis of 4-Alkylpiperidinium Salts
(4): To a three-neck round-bottomed flask charged with 4-(cyclo)-
alkylpyridine (11a–h) 10 (12.5 mmol, 1.0 equiv.) were added HCl in
methanol (1.25 M, 25.0 mL, 31.3 mmol, 2.5 equiv.) and PtO2 (0.14 g,
0.63 mmol, 0.05 equiv.). The flask was evacuated and flushed with
H2 (3 ×) using a balloon. The mixture was stirred overnight at room
temperature under hydrogen atmosphere. Upon completion, the
reaction mixture was filtered through Celite and the residue was
washed with additional methanol. The filtrate was concentrated un-
der reduced pressure to afford the title products generally as a
white solid.
Synthesis of 4-Propylpyridine (11b): Prepared according to gen-
eral procedure I using bromoethane (1.72 mL, 23 mmol, 1 equiv.).
Flash chromatography (cyclohexane/EtOAc = 3:2) provided the
product as a yellow liquid (2.69 g, 22.2 mmol, 97 %). RF = 0.37
(cyclohexane/EtOAc = 1:1); 1H NMR (CDCl3, 500 MHz): δ 8.39 (d, J =
5.9 Hz, 2H), 7.01 (d, J = 5.9 Hz, 2H), 2.49 (t, J = 7.5 Hz, 2H), 1.56 (tq,
J = 7.5, 7.5 Hz, 2H), 0.86 (t, J = 7.5 Hz, 3H) ppm; 13C NMR (CDCl3,
125 MHz): δ 151.3 (Cq), 149.3 (CH), 123.7 (CH), 37.0 (CH2), 23.2 (CH2),
13.5 (CH3) ppm; IR (neat): ν̃max (cm–1) = 2960, 2933, 2871, 1600,
1413, 1220, 794, 626, 445; HRMS (ESI): m/z calculated for C8H12N [M
+ H]+ 122.0964, found 122.0969.
Synthesis of 4-Butylpyridine (11c): Prepared according to general
procedure I using 1-bromopropane (2.09 mL, 23 mmol, 1 equiv.).
Flash chromatography (cyclohexane/EtOAc = 3:1) provided the
product as a yellow liquid (3.01 g, 22.3 mmol, 97 %). RF = 0.23
(cyclohexane/EtOAc = 3:1); 1H NMR (CDCl3, 500 MHz): δ 8.39 (d, J =
5.8 Hz, 2H), 7.02 (d, J = 5.8 Hz, 2H), 2.51 (t, J = 7.5 Hz, 2H), 1.52 (tt,
J = 7.5, 7.5 Hz, 2H), 1.26 (tq, J = 7.5, 7.5 Hz, 2H), 0.85 (t, J = 7.5 Hz,
3H) ppm; 13C NMR (CDCl3, 125 MHz): δ 151.5 (Cq), 149.4 (CH), 123.7
(CH), 34.7 (CH2), 32.2 (CH2), 22.0 (CH2), 13.6 (CH3) ppm; IR (neat):
ν̃max (cm–1) = 2965, 2931, 2860, 1600, 1413, 993, 804, 733, 630, 582,
526, 501; HRMS (ESI): m/z calculated for C9H14N [M + H]+ 136.1121,
found 136.1121.
Synthesis of 4-Isobutylpyridine (11d): Prepared according to gen-
eral procedure I using 2-bromopropane (2.16 mL, 23 mmol, 1
equiv.). Flash chromatography (cyclohexane/EtOAc = 5:1) provided
the product as a colorless oily liquid (2.67 g, 19.7 mmol, 86 %). RF =
0.40 (cyclohexane/EtOAc = 2:1); 1H NMR (CDCl3, 500 MHz): δ 8.37
(d, J = 5.8 Hz, 2H), 6.94 (d, J = 5.8 Hz, 2H), 2.33 (d, J = 7.3 Hz, 2H),
1.77 (tqq, J = 7.3, 7.3, 7.3 Hz, 1H), 0.78 (d, J = 7.3 Hz, 6H) ppm; 13C
NMR (CDCl3, 125 MHz): δ 150.1 (Cq), 149.2 (CH), 124.2 (CH), 44.3
(CH2), 29.2 (CH), 22.0 (CH3) ppm; IR (neat): ν̃max (cm–1) = 2965, 2925,
2898, 1602, 1415, 784, 630, 595, 536, 490; HRMS (ESI): m/z calculated
for C9H14N [M + H]+ 136.1121, found 136.1122.
Synthesis of 4-Pentylpyridine (11f): Prepared according to gen-
eral procedure I using 1-bromobutane (2.47 mL, 23 mmol, 1 equiv.).
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Flash chromatography (cyclohexane/EtOAc = 5:1) provided the
product as a yellow liquid (3.07 g, 20.6 mmol, 90 %). RF = 0.45
(cyclohexane/EtOAc = 2:1); 1H NMR (CDCl3, 500 MHz): δ 8.49 (bs,
2H), 7.10 (bs, 2H), 2.59 (t, J = 7.5 Hz, 2H), 1.62 (p, J = 7.5 Hz, 2H),
1.32 (m, 4H), 0.89 (t, J = 7.5 Hz, 3H) ppm; 13C NMR (CDCl3, 125 MHz):
δ 151.7 (Cq), 149.6 (CH), 123.9 (CH), 35.2 (CH2), 31.3 (CH2), 30.0 (CH2),
22.4 (CH2), 14.0 (CH3) ppm; IR (neat): ν̃max (cm–1) = 2965, 2927, 2858,
1600, 1413, 991, 798, 630, 536, 503, 496; HRMS (ESI): m/z calculated
for C10H16N [M + H]+ 150,1277, found 150.1278.
Synthesis of 4-Cyclopentylpyridine (11g): Prepared according to
general procedure II using 1,4-dibromobutane (2.75 mL, 23 mmol,
1 equiv.). Flash chromatography (cyclohexane/EtOAc = 3:1) pro-
vided the title product as a yellow liquid (0.82 g, 5.57 mmol, 24 %).
RF = 0.33 (cyclohexane/EtOAc = 2:1) 1H NMR (CDCl3, 500 MHz): δ
8.47 (d, J = 4.8 Hz, 2H), 7.14 (d, J = 4.8 Hz, 2H), 2.97 (tt, J = 8.3,
8.3 Hz, 1H), 2.07 (m, 2H), 1.81 (m, 2H), 1.69 (m, 2H), 1.58 (m, 2H)
ppm; 13C NMR (CDCl3, 125 MHz): δ 155.5 (Cq), 149.6 (CH), 122.6 (CH),
45.1 (CH), 33.9 (CH2), 25.5 (CH2) ppm; IR (neat): ν̃max (cm–1) = 2948,
2867, 1596, 1409, 993, 813, 630, 545, 493; HRMS (ESI): m/z calculated
for C10H14N [M + H]+ 148.1121, found 148.1120.
Synthesis of 4-Cyclohexylpyridine (11h): Prepared according to
general procedure II using 1,4-dibromopentane (3.13 mL, 23 mmol,
1 equiv.). Column chromatography (cyclohexane/EtOAc = 3:1) pro-
vided the title product as a yellow liquid (0.91 g, 5.66 mmol, 25 %).
RF = 0.34 (cyclohexane/EtOAc = 3:1); 1H NMR (CDCl3, 500 MHz): δ
8.47 (d, J = 4.8 Hz, 2H), 7.11 (d, J = 4.8 Hz, 2H), 2.48 (m, 1H), 1.85
(m, 4H), 1.75 (d, J = 12.5 Hz, 1H), 1.40 (m, 4H), 1.25 (m, 1H) ppm;
13C NMR (CDCl3, 125 MHz): δ 156.5 (Cq), 149.7 (CH), 122.4 (CH), 43.8
(CH), 33.5 (CH2), 36.50 (CH2), 25.9 (CH2) ppm; IR (neat): ν̃max (cm–1) =
2923, 2850, 1597, 1448, 1409, 991, 811, 622, 555, 493, 420; HRMS
(ESI): m/z calculated for C11H16N [M + H]+ 162.1277, found 162.1278.
Synthesis of 4-Ethylpiperidine Hydrochloride (4a): Prepared ac-
cording to general procedure III from commercial 4-ethylpyridine
(1.34 g, 12.5 mmol, 1 equiv.). The title compound was isolated as a
white solid (1.87 g, 12.5 mmol, 100 %). m.p. 176 °C; 1H NMR (CDCl3,
500 MHz): δ 9.53 (bs, 1H), 9.21 (bs, 1H), 3.45 (m, 2H), 2.83 (m, 2H),
1.88 (d, J = 13.0 Hz, 2H), 1.59 (m, 2H), 1.46–1.25 (m, 3H), 0.88 (t, J =
7.0 Hz, 3H) ppm; 13C NMR (CDCl3, 125 MHz): δ 44.1 (CH2), 35.8 (CH),
28.4 (CH2), 28.4 (CH2), 10.9 (CH3) ppm; IR (neat): ν̃max (cm–1) = 2973,
2794, 2727, 2497, 1593, 1456, 1396, 1076, 993, 574, 441; HRMS (ESI):
m/z calculated for C7H16N [M + H]+ 114.1277, found 114.1281.
Synthesis of 4-Propylpiperidine Hydrochloride (4b): Prepared ac-
cording to general procedure III from 11c (1.51 g, 12.5 mmol, 1
equiv.). The title compound was isolated as an off-white solid
(2.04 g, 12.5 mmol, 100 %). m.p. 203 °C; 1H NMR (CDCl3, 500 MHz):
δ 9.53 (bs, 1H), 9.22 (bs, 1H), 3.44 (m, 2H), 2.82 (m, 2H), 1.93 (d, J =
12.5 Hz, 2H), 1.64–1.44 (m, 3H), 1.27 (m, 4H), 0.87 (t, J = 6.5 Hz, 3H)
ppm; 13C NMR (CDCl3, 125 MHz): δ 44.1 (CH2), 37.8 (CH2), 33.8 (CH),
28.7 (CH2), 19.4 (CH2) 14.0 (CH3) ppm; IR (neat): ν̃max (cm–1) = 2941,
2923, 2796, 2718, 1591, 1456, 1392, 1074, 956, 574; HRMS (ESI): m/z
calculated for C8H18N [M + H]+ 128.1434, found 128.1434.
Synthesis of 4-Butylpiperidine Hydrochloride (4c): Prepared ac-
cording to general procedure III from 11c (1.69 g, 12.5 mmol, 1
equiv.). The title compound was isolated as an off-white solid
(2.22 g, 12.5 mmol, 100 %). m.p. 204 °C; 1H NMR (CDCl3, 500 MHz):
δ 9.50 (bs, 1H), 9.21 (bs, 1H), 3.43 (m, 2H), 2.81 (m, 2H), 1.84 (d, J =
12.5 Hz, 2H), 1.59 (m, 2H), 1.45 (m, 1H), 1.24 (m, 6H), 0.84 (t, J =
6.3 Hz, 3H) ppm; 13C NMR (CDCl3, 125 MHz): δ 44.1 (CH2), 35.3 (CH2),
34.0 (CH), 28.7 (CH2), 28.5 (CH2), 22.6 (CH2), 13.9 (CH3) ppm; IR (neat):
ν̃max (cm–1) = 2947, 2920, 2844, 2792, 2769, 2719, 1591, 1448, 1074,
943, 576, 439; HRMS (ESI): m/z calculated for C9H20N [M + H]+
142.1590, found 142.1587.
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Synthesis of 4-(Isobutyl)piperidine Hydrochloride (4d): Prepared
according to general procedure III from 11d (1.69 g, 12.5 mmol, 1
equiv.). The title compound was isolated as a white solid (2.21 g,
12.5 mmol, 100 %). m.p. 259 °C; 1H NMR (CDCl3, 500 MHz): δ 9.57
(bs, 1H), 9.25 (bs, 1H), 3.46 (m, 2H), 2.84 (m, 2H), 1.85 (m, 2H), 1.61
(m, 4H), 1.17 (m, 2H), 0.86 (d, J = 6.2 Hz, 6H) ppm; 13C NMR (CDCl3,
125 MHz): δ 44.9 (CH2), 44.1 (CH2), 31.7 (CH), 28.9 (CH2), 24.4 (CH),
22.6 (CH3) ppm; IR (neat): ν̃max (cm–1) = 2890, 2796, 2769, 2736,
1589, 1448, 595, 499; HRMS (ESI): m/z calculated for C9H20N [M +
H]+ 142.1590, found 142.1587.
Synthesis of 4-(tert-Butyl)piperidine Hydrochloride (4e): Pre-
pared according to general procedure III from commercial 4-tert-
butylpyridine (1.69 g, 12.5 mmol, 1 equiv.) with additional PtO2
(0.10 equiv. instead of 0.05 equiv.) and a prolonged reaction time
(36 h instead of overnight). The title compound was isolated as a
white solid (2.07 g, 12.5 mmol, 93 %). m.p. 303 °C; 1H NMR (CDCl3,
500 MHz): δ 9.54 (bs, 1H), 9.23 (bs, 1H), 3.53 (d, J = 12.0 Hz, 2H),
2.79 (q, J = 12.0 Hz, 2H), 1.85 (d, J = 12.0 Hz, 2H), 1.70 (q, J = 12.0 Hz,
2H), 1.21 (t, J = 12.0 Hz, 1H), 0.87 (s, 9H) ppm; 13C NMR (CDCl3,
125 MHz): δ 44.8 (CH), 44.7 (CH2), 32.3 (Cq), 27.0 (CH3), 23.9 (CH2)
ppm; IR (neat): ν̃max (cm–1) = 2960, 2837, 2798, 2777, 2761, 2744,
2719, 1591, 1448, 1396, 1361, 1078, 568, 509; HRMS (ESI): m/z calcu-
lated for C9H20N [M + H]+ 142.1590, found 142.1588.
Synthesis of 4-Pentylpiperidine Hydrochloride (4f): Prepared ac-
cording to general procedure III from 11f (1.87 g, 12.5 mmol, 1
equiv.). The title compound was isolated as an off-white solid
(2.39 g, 12.5 mmol, 100 %). m.p. 201 °C; 1H NMR (CDCl3, 500 MHz):
δ 9.55 (bs, 1H), 9.23 (bs, 1H), 3.45 (m, 2H), 2.81 (m, 2H), 1.87 (d, J =
12.5 Hz, 2H), 1.60 (m, 2H), 1.47 (m, 1H), 1.26 (m, 8H), 0.86 (t, J =
6.5 Hz, 3H) ppm; 13C NMR (CDCl3, 125 MHz): δ 44.1 (CH2), 35.6 (CH2),
34.1 (CH), 31.8 (CH2), 28.8 (CH2), 26.0 (CH2), 22.5 (CH2), 14.0 (CH3)
ppm; IR (neat): ν̃max (cm–1) = 2945, 2910, 2846, 2792, 2767, 2734,
1589, 1448, 1396, 1074, 576, 437; HRMS (ESI): m/z calculated for
C10H22N [M + H]+ 156.1747, found 156.1746.
Synthesis of 4-Cyclopentylpiperidine Hydrochloride (4g): Pre-
pared according to general procedure III from 11g (0.72 g,
4.89 mmol, 1 equiv.) on a smaller scale. The title compound was
isolated as an off-white solid (0.92 g, 4.85 mmol, 99 %). m.p. 238 °C;
1H NMR (CDCl3, 500 MHz): δ 9.45 (bs, 1H), 9.16 (bs, 1H), 3.45 (m,
2H), 2.81 (m, 2H), 1.98–1.43 (m, 9H), ), 1.24 (m, 1H) 1.05 (m, 2H)
ppm; 13C NMR (CDCl3, 125 MHz): δ 45.1 (CH), 44.3 (CH2), 39.9 (CH),
30.2 (CH2), 27.9 (CH2), 25.0 (CH2) ppm; IR (neat): ν̃max (cm–1) = 2966,
2850, 2792, 2765, 2738, 2704, 2495, 1589, 1444, 1396, 1076, 522;
HRMS (ESI): m/z calculated for C10H20N [M + H]+ 154.1590, found
154.1588.
Synthesis of 4-Cyclohexylpiperidine Hydrochloride (4h): Pre-
pared according to general procedure III from 11h (0.68 g,
4.22 mmol, 1 equiv.) on a smaller scale. The title compound was
isolated as an off-white solid (0.79 g, 3.88 mmol, 92 %). m.p. 310 °C;
1H NMR (CDCl3, 500 MHz): δ 9.51 (bs, 1H), 9.19 (bs, 1H), 3.48 (d, J =
12.0 Hz, 2H), 2.79 (m, 2H), 1.91–1.60 (m, 9H), 1.32–1.02 (m, 5H), 0.91
(q, J = 12.0 Hz, 2H) ppm; 13C NMR (CDCl3, 125 MHz): δ 44.4 (CH2),
41.8 (CH), 39.8 (CH), 29.9 (CH2), 26.4 (CH2), 26.3 (CH2) 26.1 (CH2)
ppm; IR (neat): ν̃max (cm–1) = 2964, 2848, 2794, 2777, 2727, 1450,
541; HRMS (ESI): m/z calculated for C11H22N [M + H]+ 168.1747,
found 168.1745.
Synthesis of the Pipecolic Amides (6)
General Procedure IV: 3-Step Synthesis of the U-3CR Products:
The 4-alkyl piperidinium salt 4 (6.0 mmol, 1 equiv.) was dissolved
in water and the pH was increased to >11 by addition of aqueous
NH4OH (25 % w/w). The resulting solution was extracted CH2Cl2
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(2 ×). The organic layers where combined, washed with brine, dried
with anhydrous Na2SO4 and concentrated under reduced pressure.
The remaining oil was redissolved in CH2Cl2 (25 mL) and the solu-
tion was cooled to 0 °C. Then, N-chlorosuccinimide (0.82 g,
6.12 mmol, 1.02 equiv.) was added portion-wise (over 5 min) to the
solution. The ice bath was removed and the resulting mixture was
stirred for 3 h until TLC indicated a clear sign of the chlorinated
species (clearly visible under UV at relatively high RF values). Upon
completion, the reaction mixture was washed with water (2 ×) and
with brine, dried with anhydrous Na2SO4 and concentrated under
reduced pressure. The remaining oil was redissolved in CH2Cl2
(15 mL) and slowly added to a solution of KOH (0.71 g, 12.6 mmol,
2.1 equiv.) in EtOH (15 mL) and the resulting mixture was stirred
overnight. Upon completion, the mixture was filtered and the fil-
trate was concentrated under reduced pressure. The remaining mix-
ture was dissolved in CH2Cl2, washed with water (2 ×) and with
brine, dried with anhydrous Na2SO4 and the solvent was removed
under reduced pressure to afford the corresponding imine 5.
Batches of 1.0 mmol of crude imine were used in the U-3CR reaction
without further purification. Thus, in a round-bottom flask,
5 (1 mmol, 1 equiv.) was dissolved in CH2Cl2 (2 mL). Then, the iso-
cyanide 13 (1.2 mmol, 1.2 equiv.) and the carboxylic acid 14
(1.2 mmol, 1.2 equiv.) were added sequentially and the resulting
mixture was stirred for 48 h. More CH2Cl2 (5 mL) was added and
the resulting solution was washed with saturated aqueous Na2CO3
and with brine, dried with anhydrous Na2SO4 and the solvent was
evaporated under reduced pressure. The crude product was purified
by flash column chromatography to obtain the product generally
as a white solid.
Synthesis of N-Cyclohexyl-4-ethyl-1-pivaloylpiperidine-2-
carbox-amide (6a): The general procedure IV with 0.90 g
(6.0 mmol, 1 equiv.) of 4a gave 0.54 g (4.86 mmol, 81 %.) of 3,4,5,6-
tetrahydro-4-ethylpyridine 5b. An 1.0 mmol aliquot of 5b (111 mg,
1 equiv.) was then used in the U-3CR together with pivalic acid
(123 mg, 1.2 mmol, 1.2 equiv.) and cyclohexyl isocyanide (149 μL,
1.2 mmol, 1.2 equiv.) following the general procedure IV. Flash chro-
matography (cyclohexane/EtOAc = 6:1) provided the 6a as a white
solid (254 mg, 0.79 mmol, 79 %). RF = 0.66 (cyclohexane/EtOAc =
2:1); m.p. 107–108 °C; 1H NMR (CDCl3, 500 MHz): δ 6.08 (bs, 1H),
5.09 (m, 1H), 4.16 (m, 1H), 3.72 (q, J = 4.3 Hz, 1H), 2.88 (m, 1H), 2.28
(d, J = 12.8 Hz, 1H), 1.87–1.51 (m, 7H), 1.34–0.95 (m, 19H), 0.87 (t,
J = 7.0 Hz, 3H) ppm; 13C NMR (CDCl3, 125 MHz): δ 178.2 (Cq), 170.0
(Cq), 47.6 (CH), 44.0 (Cq), 38.8 (CH2), 33.4 (CH), 33.1 (CH2), 32.7 (CH2),
31.7 (CH2), 31.4 (CH2), 29.4 (CH2), 28.2 (CH3), 25.4 (CH2), 24.5 (CH2),
10.9 (CH3) ppm; IR (neat): ν̃max (cm–1) = 3325, 2928, 2854, 1670,
1610, 1522, 1412, 1188, 919, 729, 646; HRMS (ESI): m/z calculated
for C19H34N2NaO2 [M + Na]+ 345.2512, found 345.2512.
Synthesis of N-(tert-Butyl)-4-ethyl-1-(2-(4-methoxyphenyl)-
acetyl)-piperidine-2-carboxamide (6b): Another 1.0 mmol aliquot
of 5b (111 mg, 1 equiv., see preparation of 6a) was then used
in the U-3CR together with 4-methoxyphenylacetic acid (199 mg,
1.2 mmol, 1.2 equiv.) and tert-butyl isocyanide (135 μL, 1.2 mmol,
1.2 equiv.) following the general procedure IV. Flash chromatogra-
phy (cyclohexane/EtOAc = 4:1) provided 6b as an off-white solid
(292 mg, 0.81 mmol, 81 %). Two rotamers were present on NMR-
timescale in a 1:0.28 ratio. RF = 0.41 (cyclohexane/EtOAc = 2:1); m.p.
90 °C; 1H NMR (CDCl3, 500 MHz): δ 7.16 (m, 2.56H), 6.83 (d, J =
8.6 Hz, 2.56H), 5.9 (bs, 1H), 5.25 (bs, 0.28H), 5.15 (d, J = 5.5 Hz, 1H),
4.62 (d, J = 11.6 Hz, 0.28H), 4.44 (d, J = 5.0 Hz, 0.28H), 3.89–3.61 (m,
7.40H), 2.90 (t, J = 11.4 Hz, 1H), 2.43 (m, 0.56H), 2.21 (d, J = 12.0 Hz,
1H), 1.78–1.60 (m, 2.28H), 1.30–1.08 (m, 14.36H), 1.05–0.79 (m,
6.40H) ppm; 13C NMR (CDCl3, 125 MHz): δ 171.3 (Cq), 171.1 (Cq),
169.9 (Cq), 168.1 (Cq), 158.6 (Cq), 158.5 (Cq), 129.4 (CH), 129.3 (CH),
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126.6 (Cq), 126.4 (Cq), 114.5 (CH), 114.2 (CH), 58.3 (CH), 55.2 (CH),
55.2 (CH3), 52.4 (CH3), 51.0 (Cq), 50.8 (Cq), 44.1 (CH2), 40.7 (CH2), 40.1
(CH2), 39.9 (CH2), 33.7 (CH), 33.0 (CH), 32.4 (CH2), 31.4 (CH2), 31.2
(CH2), 30.7 (CH2), 29.3 (CH2), 29.1 (CH2), 28.6 (CH3), 28.3 (CH3), 10.8
(CH3), 10.7 (CH3); IR (neat): ν̃max (cm–1) = 3325, 2959, 1624, 1510,
1452, 1246, 1036, 920, 731, 644, 523; HRMS (ESI): m/z calculated for
C21H33N2O3 [M + H]+ 361.2486, found 361.2465.
Synthesis of N-Pentyl-1-pivaloyl-4-propylpiperidine-2-carbox-
amide (6c): The general procedure IV with 0.98 g (6.0 mmol, 1
equiv.) of 4b gave 0.64 g (5.1 mmol, 85 %.) of 3,4,5,6-tetrahydro-4-
propylpyridine 5c. An 1.0 mmol aliquot of 5c (125 mg, 1 equiv.) was
then used in the U-3CR together with pivalic acid (123 mg,
1.2 mmol, 1.2 equiv.) and cyclohexyl isocyanide (151 μL, 1.2 mmol,
1.2 equiv.) following the general procedure IV. Flash chromatogra-
phy (cyclohexane/EtOAc = 5:1) provided 6c as a slowly crystallizing
oil (254 mg, 0.78 mmol, 78 %.). RF = 0.58 (cyclohexane/EtOAc = 2:1);
1H NMR (CDCl3, 500 MHz): δ 6.21 (bs, 1H), 5.10 (bs, 1H), 4.15 (m,
1H), 3.26 (m, 1H), 3.11 (m, 1H), 2.92 (m, 1H), 2.27 (d, J = 12.9 Hz,
1H), 1.85 (m, 1H), 1.67 (d, J = 12.9 Hz, 1H), 1.42 (m, 2H), 1.33–1.10
(m, 17H), 1.10–0.99 (m, 2H), 0.86 (m, 6H) ppm; 13C NMR (CDCl3,
125 MHz): δ 178.3 (Cq), 171.0 (Cq), 45.3 (CH), 44.2 (Cq), 39.1 (CH2),
38.9 (CH2), 38.9 (CH2), 32.0 (CH2), 31.8 (CH2), 31.4 (CH), 29.3 (CH2),
29.0 (CH2), 28.2 (CH3), 22.2 (CH2), 19.5 (CH2), 14.2 (CH3), 13.9 (CH3)
ppm; IR (neat): ν̃max (cm–1) = 3337, 2955, 2928, 1670, 1612, 1521,
1412, 1186, 630, 532; HRMS (ESI): m/z calculated for C19H36N2NaO2
[M + Na]+ 347.2669, found 347.2670.
Synthesis of 1-Benzoyl-N-(tert-butyl)-4-propylpiperidine-2-
carbox-amide (6d): Another 1.0 mmol aliquot of 5c (125 mg,
1 equiv., see preparation of 6c) was then used in the U-3CR together
with benzoic acid (147 mg, 1.2 mmol, 1.2 equiv.) and tert-butyl iso-
cyanide (135 μL, 1.2 mmol, 1.2 equiv.) following the general proce-
dure IV. Flash chromatography (cyclohexane/EtOAc = 4:1) provided
6d as a slowly crystallizing white solid (271 mg, 0.82 mmol, 82 %).
Two rotamers were present on NMR-timescale in a 1:0.21 ratio. RF =
0.57 (cyclohexane/EtOAc = 2:1); m.p. 92 °C; 1H NMR (CDCl3,
500 MHz): δ 7.44–7.26 (m, 6.05H), 6.41 (s, 1H), 5.81 (s, 0.21H), 5.17
(d, J = 5.4Hz, 1H), 4.72 (d, J = 12.8 Hz, 0.21H), 4.29 (bs, 0.21H), 3.76
(d, J = 13.6 Hz, 1H), 3.01 (t, J = 11.6 Hz, 1H), 2.79 (t, J = 12.6 Hz,
0.21H), 2.78 (d, J = 13.2 Hz, 1.21H), 1.96 (m, 1H), 1.75 (d, J = 12.7 Hz,
0.21H), 1.62 (d, J = 12.8 Hz, 1H), 1.50 (m, 0.42H), 1.40–1.02 (m,
18.15H), 0.87 (m, 3.63H) ppm; 13C NMR (CDCl3, 125 MHz): δ 172.0
(Cq), 171.8 (Cq), 170.0 (Cq), 168.8 (Cq), 135.5 (Cq), 135.3 (Cq), 130.1
(CH), 129.9 (CH), 128.7 (CH), 128.5 (CH), 126.9 (CH), 126.1 (CH), 59.7
(CH), 53.2 (CH), 51.5 (Cq), 50.9 (Cq), 45.8 (CH2), 40.2 (CH2), 39.0 (CH2),
38.6 (CH2), 33.4 (CH2), 33.1 (CH2), 32.1 (CH2), 31.8 (CH), 31.4 (CH),
31.3 (CH2), 28.8 (CH3), 28.7 (CH3), 19.5 (CH2), 19.4 (CH2), 14.3 (CH3),
14.1 (CH3) ppm; IR (neat): ν̃max (cm–1) = 3337, 2959, 2926, 1683,
1616, 1522, 1423, 1363, 1253, 1224, 1203, 921, 730, 700, 646; HRMS
(ESI): m/z calculated for C20H31N2O2 [M + H]+ 331.2380, found
331.2367.
Synthesis of Methyl (1-Acetyl-4-butylpiperidine-2-carbonyl)-
glycinate (6e): The general procedure IV with 1.07 g (6.0 mmol, 1
equiv.) of 4c gave 0.78 g (5.6 mmol, 93 %.) of 3,4,5,6-tetrahydro-4-
butylpyridine 5d. An 1.0 mmol aliquot of 5d (139 mg, 1 equiv.) was
then used in the U-3CR together with acetic acid (69 μL, 1.2 mmol,
1.2 equiv.) and methyl isocyanoacetate (109 μL, 1.2 mmol,
1.2 equiv.) following the general procedure IV. Flash chromatogra-
phy (EtOAc) provided 6e as a slowly crystallizing oil (205 mg,
0.69 mmol, 69 %). Two rotamers were present on NMR-timescale in
a 1:0.27 ratio. RF = 0.25 (EtOAc); 1H NMR (CDCl3, 500 MHz): δ 7.27
(bs, 0.27H), 6.69 (bs, 1H), 5.28 (d, J = 5.5 Hz, 1H), 4.59 (d, J = 13.5 Hz,
0.27H), 4.46 (d, J = 5.2 Hz, 0.27H), 4.14 (m, 1.27H), (dd, J = 17.8,
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5.5 Hz, 0.27H), 3.80–3.70 (m, 5.81H), 3.21 (dt, J = 13.8, 2.2 Hz, 1H),
2.71 (dt, J = 13.3, 2.5 Hz, 0.27H), 2.52 (d, J = 12.4 Hz, 0.27H), 2.26
(d, J = 12.2 Hz, 1H), 2.16 (s, 3H), 2.11 (s, 0.81H), 1.93 (bs, 0.27H),
1.80–1.63 (m, 2.27H), 1.43 (bs, 0.27H), 1.80–1.63 (m, 9.89H), 0.86 (t,
J = 6.8 Hz, 3.81H) ppm; 13C NMR (CDCl3, 125 MHz): δ 171.4 (Cq),
170.9 (Cq), 170.4 (Cq), 170.4 (Cq), 170.3 (Cq), 170.2 (Cq), 58.2 (CH),
52.3 (CH), 52.2 (CH3), 51.8 (CH3), 44.4 (CH2), 41.0 (CH2), 40.8 (CH2),
39.5 (CH2), 36.3 (CH2), 36.1 (CH2), 33.0 (CH2), 32.1 (CH), 31.9 (CH2),
31.7 (CH2), 31.5 (CH), 31.2 (CH2), 29.7 (CH2), 28.5 (CH2), 28.5 (CH2),
22.7 (CH2), 21.7 (CH3), 21.7 (CH3), 14.0 (CH3), 14.0 (CH3) ppm; IR
(neat): ν̃max (cm–1) = 3330, 2925, 1751, 1629, 1521, 1423, 1363, 1201,
644, 572, 463; HRMS (ESI): m/z calculated for C15H27N2O4 [M + H]+
299.1965, found 299.1949.
Synthesis of N-(tert-Butyl)-4-butyl-1-(pent-4-enoyl)piperidine-
2-carboxamide (6f): Another 1.0 mmol aliquot of 5d (139 mg, 1
equiv.) was then used in the U-3CR together with 4-pentenoic acid
(123 μL, 1.2 mmol, 1.2 equiv.) and tert-butyl isocyanide (135 μL,
1.2 mmol, 1.2 equiv.) following the general procedure IV. Flash chro-
matography (cyclohexane/EtOAc = 4:1) provided 6f as a white solid
(270 mg, 0.84 mmol, 84 %). Two rotamers were present on NMR-
timescale in a 1:0.25 ratio. RF = 0.58 (cyclohexane/EtOAc = 2:1) m.p.
89 °C; 1H NMR (CDCl3, 500 MHz): δ 5.97 (s, 1H), 5.84 (m, 1.25H), 5.70
(s, 0.25H), 5.11 (d, J = 6.5Hz, 1H), 5.05 (d, J = 17.2 Hz, 1.25H), 4.99
(d, J = 10.2 Hz, 1.25H), 4.63 (d, J = 11.7 Hz, 0.25H), 4.38 (d, J = 5.4 Hz,
0.25H), 3.76 (d, J = 13.6 Hz, 1H), 3.05 (dt, J = 13.3, 2.5 Hz, 1H), 2.55–
2.31 (m, 5.5H), 2.18 (d, J = 13.5 Hz, 1H), 1.83 (m, 1H), 1.70 (m, 1.25H),
1.31–1.12 (m, 19.0H) 1.08–0.95 (m, 2.5H), 0.85 (t, J = 7.0 Hz, 3.75H)
ppm; 13C NMR (CDCl3, 125 MHz): δ 172.4 (Cq), 172.0 (Cq), 170.2 (Cq),
168.7 (Cq), 137.1 (CH2)2), 137.0 (CH2)2), 115.6 (CH), 115.4 (CH), 57.7
(CH), 52.5 (CH), 51.5 (Cq), 50.8 (Cq), 43.5 (CH2)2), 39.7 (CH2)2), 36.4
(CH2)2), 36.1 (CH2)2), 33.0 (CH2)2), 32.7 (CH2)2), 32.6 (CH2)2), 32.3 (CH),
32.1 (CH2)2), 31.8 (CH2)2), 31.6 (CH), 31.2 (CH2)2), 29.2 (CH2)2), 29.2
(CH2)2), 28.7 (CH3), 28.7 (CH3), 28.6 (CH2)2), 28.5 (CH2), 22.8 (CH2),
22.8 (CH2), 14.0 (CH2), 14.0 (CH2) ppm; IR (neat): ν̃max (cm–1) = 3329,
2924 1676, 1628, 1541, 1452, 1425, 1363, 910, 731, 646; HRMS (ESI):
m/z calculated for C19H34N2NaO2 [M + Na]+ 345.2512, found
345.2528.
Synthesis of N-Cyclohexyl-4-isobutyl-1-pivaloylpiperidine-2-
carbox-amide (6g): The general procedure IV with 1.07 g
(6.0 mmol, 1 equiv.) of 4d gave 0.75 g (5.4 mmol, 90 %.) of 3,4,5,6-
tetrahydro-4-isobutylpyridine 5e. An 1.0 mmol aliquot of 5e
(139 mg, 1 equiv.) was then used in the U-3CR together with pivalic
acid (123 mg, 1.2 mmol, 1.2 equiv.) and cyclohexyl isocyanide
(149 μL, 1.2 mmol, 1.2 equiv.) following the general procedure IV.
Flash chromatography (cyclohexane/EtOAc = 6:1) provided the 6g
as a white crystalline solid (286 mg, 0.81 mmol, 81 %). RF = 0.64
(cyclohexane/EtOAc = 2:1); m.p. 96 °C; 1H NMR (CDCl3, 500 MHz): δ
6.13 (bs, 1H), 5.10 (bs, 1H), 4.16 (bs, 1H), 3.74 (m, 1H), 2.91 (m, 1H),
2.27 (d, J = 11.8 Hz, 1H), 1.95 (bs, 1H), 1.84 (d, J = 9.2 Hz, 1H), 1.76
(d, J = 9.1 Hz, 1H), 1.72–1.59 (m, 4H), 2.27 (d, J = 9.1 Hz, 1H), 1.40–
1.24 (m, 1H), 1.20–0.96 (m, 7H), 0.89 (d, J = 6.6 Hz, 3H), 0.85 (d, J =
6.6 Hz, 3H) ppm; 13C NMR (CDCl3, 125 MHz): δ 178.3 (Cq), 170.1 (Cq),
47.6 (CH), 46.1 (CH2), 44.2 (CH), 38.8 (Cq), 33.2 (CH2), 32.8 (CH2), 32.3
(CH2), 31.9 (CH2), 29.4 (CH), 28.2 (CH3), 25.4 (CH2), 24.6 (CH2), 24.5
(CH), 22.9 (CH3), 22.5 (CH3) ppm; IR (neat): ν̃max (cm–1) = 3339, 2930,
2853, 1678, 1610, 1518, 1412, 1366, 1186, 976, 920, 731, 646, 467;
HRMS (ESI): m/z calculated for C21H38N2NaO2 [M + Na]+ 373.2825,
found 373.2833.
Synthesis of 1-Benzoyl-N-(tert-butyl)-4-isobutylpiperidine-2-
carbox-amide (6h): Another 1.0 mmol aliquot of 5e (139 mg,
1 equiv., see preparation of 6g) was then used in the U-3CR to-
gether with benzoic acid (147 mg, 1.2 mmol, 1.2 equiv.) and tert-
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butyl isocyanide (135 μL, 1.2 mmol, 1.2 equiv.) following the general
procedure IV. Flash chromatography (cyclohexane/EtOAc = 7:2) pro-
vided 6h as a white solid (294 mg, 0.91 mmol, 91 %). Two rotamers
were present on NMR-timescale in a 1:0.23 ratio. RF = 0.57 (cyclo-
hexane/EtOAc = 2:1); m.p. 115 °C; 1H NMR (CDCl3, 500 MHz): δ 7.45–
7.35 (m, 6.15H), 6.39 (bs, 1H), 5.78 (bs, 0.23H), 5.18 (d, J = 5.4 Hz,
1H), 4.73 (d, J = 12.6 Hz, 0.23H), 4.30 (bs, 0.23H), 3.67 (d, J = 13.7 Hz,
1H), 3.01 (t, J = 12.1 Hz, 1H), 2.82 (t, J = 12.1 Hz, 0.23H), 2.28 (d, J =
13.3 Hz, 1.23H), 2.03 (m, 1H), 1.76–1.64 (m, 1.69H), 1.61 (d, J =
12.8 Hz, 1.23H), 1.35 (s, 11.07H), 1.19–1.01 (m, 4.92H), 0.91 (d, J =
6.6 Hz, 3.69H), 0.88 (d, J = 6.6 Hz, 3.69H) ppm; 13C NMR (CDCl3,
125 MHz): δ 172.0 (Cq), 171.9 (Cq), 170.0 (Cq), 168.8 (Cq), 135.5 (Cq),
135.3 (Cq), 130.1 (CH), 130.0 (CH), 128.8 (CH), 128.6 (CH), 127.0 (CH),
126.1 (CH), 59.7 (CH), 53.3 (CH), 51.6 (Cq), 50.9 (Cq), 46.3 (CH2), 45.8
(CH2), 45.8 (CH2), 40.3 (CH2), 33.2 (CH2), 32.5 (CH2), 31.9 (CH2), 31.7
(CH2), 30.0 (CH), 29.4 (CH), 28.8 (CH3), 28.7 (CH3), 24.6 (CH), 24.5
(CH), 22.9 (CH3), 22.8 (CH3), 22.7 (CH3), 22.6 (CH3) ppm; IR (neat):
ν̃max (cm–1) = 3327, 2957, 1682, 1620, 1533, 1425, 1366, 1254, 700;
HRMS (ESI): m/z calculated for C21H33N2O2 [M + H]+ 345.2537, found
345.2529.
Synthesis of 1-Acetyl-4-(tert-butyl)-N-pentylpiperidine-2-
carbox-amide (6i): The general procedure IV with 1.07 g (6.0 mmol,
1 equiv.) of 4e gave 0.71 g (5.1 mmol, 85 %.) of 3,4,5,6-tetrahydro-
4-tertbutylpyridine 5f. An 1.0 mmol aliquot of 5f (139 mg, 1 equiv.)
was then used in the U-3CR together with acetic acid (69 μL,
1.2 mmol, 1.2 equiv.) and pentyl isocyanide (151 μL, 1.2 mmol,
1.2 equiv.) following the general procedure IV. Flash chromatogra-
phy (cyclohexane/EtOAc = 6:1) provided 6i as a white solid (284 mg,
0.96 mmol, 96 %). Two rotamers were present on NMR-timescale in
a 1:0.30 ratio. RF = 0.31 (cyclohexane/EtOAc = 6:1); m.p. 100 °C; 1H
NMR (CDCl3, 500 MHz): δ 6.48 (bs, 0.30H), 6.21 (bs, 1H), 5.21 (d, J =
4.6 Hz, 1H), 4.62 (d, J = 13.6 Hz, 0.30H), 4.44 (bs, 0.30H), 3.74 (d, J =
12.9 Hz, 1H), 3.26–3.08 (m, 3.60H), 2.52 (m, 0.60H), 2.22 (d, J =
13.1Hz, 1H), 2.13 (s, 3H), 2.07 (s, 0.90H), 1.72–1.51 (m, 2.30H), 1.49–
1.39 (m, 2.60H), 1.33–1.05 (m, 8.10H), 0.83 (m, 15.60H) ppm; 13C
NMR (CDCl3, 125 MHz): δ 170.8 (Cq), 170.5 (Cq), 170.2 (Cq), 169.3
(Cq), 58.5 (CH), 52.1 (CH), 44.7 (CH2), 42.3 (CH), 41.4 (CH), 39.9 (CH2),
32.0 (Cq), 32.0 (Cq), 29.2 (CH2), 29.0 (CH2), 29.0 (CH2), 27.8 (CH2), 26.9
(CH3), 26.9 (CH3), 26.6 (CH2), 26.6 (CH2), 25.9 (CH2), 22.2 (CH2), 22.2
(CH2), 21.7 (CH3), 21.6 (CH3), 13.9 (CH3), 13.9 (CH3) ppm; IR (neat):
ν̃max (cm–1) = 3319, 2955, 2868, 1631, 1529, 1423, 1365, 1259, 1186,
993, 730, 629, 528; HRMS (ESI): m/z calculated for C17H32N2NaO2 [M
+ Na]+ 319.2356, found 319.2369.
Synthesis of N,4-Di-tert-butyl-1-(pent-4-enoyl)piperidine-2-
carbox-amide (6j): Another 1.0 mmol aliquot of 5f (139 mg,
1 equiv., see preparation of 6i) was then used in the U-3CR together
with 4-pentenoic acid (123 μL, 1.2 mmol, 1.2 equiv.) and tert-butyl
isocyanide (135 μL, 1.2 mmol, 1.2 equiv.) following the general pro-
cedure IV. Flash chromatography (cyclohexane/EtOAc = 4:1) pro-
vided 6j as a white solid (312 mg, 0.97 mmol, 97 %). Two rotamers
were present on NMR-timescale in a 1:0.20 ratio. RF = 0.54. (cyclo-
hexane/EtOAc = 2:1); m.p. 126 °C; 1H NMR (CDCl3, 500 MHz): δ 5.96
(bs, 1H), 5.85 (m, 1.20H), 5.69 (bs, 0.20H), 5.16 (d, J = 5.7 Hz, 1H),
5.06 (d, J = 17.2 Hz, 1.20H), 5.00 (d, J = 10.2 Hz, 1.20H), 4.67 (d, J =
13.5 Hz, 0.20H), 4.43 (bs, 0.20H), 3.81 (d, J = 13.5 Hz, 1H), 3.05 (dt,
J = 13.2, 2.5 Hz, 1H), 2.53–2.33 (m, 5.20H), 2.19 (d, J = 13.3 Hz, 1H),
1.70 (d, J = 12.9 Hz, 1H), 1.63 (m, 1.20H), 1.33 (s, 1.80H), 1.28 (s, 9H),
1.17 (m, 2.60H), 0.85 (s, 9H), 0.84 (s, 1.80H) ppm; 13C NMR (CDCl3,
125 MHz): δ 172.3 (Cq), 171.9 (Cq), 170.3 (Cq), 168.7 (Cq), 137.1 (CH),
137.0 (CH), 115.6 (CH2), 115.4 (CH2), 57.9 (CH), 52.6 (CH), 51.1 (Cq),
50.8 (Cq), 43.9 (CH2), 42.4 (CH), 41.3 (CH), 40.2 (CH2), 32.6 (CH2), 32.5
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(CH2), 32.0 (Cq), 32.0 (Cq), 29.2 (CH2), 29.2 (CH2), 28.7 (CH3), 28.7
(CH3), 27.8 (CH2), 27.0 (CH3), 26.9 (CH3), 26.8 (CH2), 26.4 (CH2), 26.0
(CH2) ppm; IR (neat): ν̃max (cm–1) = 3323, 2959, 1682, 1626, 1541,
1450, 1363, 1263, 1224, 910, 632, 530; HRMS (ESI): m/z calculated
for C19H35N2O2 [M + H]+ 323.2693, found 323.2676.
Synthesis of N-Cyclohexyl-4-pentyl-1-pivaloylpiperidine-2-
carbox-amide (6k) : The general procedure IV with 1.15 g
(6.0 mmol, 1 equiv.) of 4f gave 0.85 g (5.5 mmol, 92 %.) of 3,4,5,6-
tetrahydro-4-pentylpyridine 5g. An 1.0 mmol aliquot of 5g (153 mg,
1 equiv.) was then used in the U-3CR together with pivalic acid
(123 mg, 1.2 mmol, 1.2 equiv.) and cyclohexyl isocyanide (149 μL,
1.2 mmol, 1.2 equiv.) following the general procedure IV. Flash chro-
matography (cyclohexane/EtOAc = 6:1) provided 6k as a white solid
(339 mg, 0.93 mmol, 93 %). RF = 0.44. (cyclohexane/EtOAc = 4:1);
m.p. 78 °C; 1H NMR (CDCl3, 500 MHz): δ 6.09 (d, J = 7.4 Hz, 1H), 5.06
(bs, 1H), 4.16 (m, 1H), 3.73 (m, 1H), 2.89 (m, 1H), 2.28 (d, J = 12.7 Hz,
1H), 1.90–1.72 (m, 3H), 1.71–1.51 (m, 4H), 1.40–0.95 (m, 24H), 0.85
(t, J = 6.7 Hz, 3H) ppm; 13C NMR (CDCl3, 125 MHz): δ 178.2 (Cq),
170.0 (Cq), 47.6 (CH), 44.1 (CH), 38.8 (Cq), 36.7 (CH2), 33.1 (CH2), 32.7
(CH2), 32.0 (CH2), 31.9 (CH2), 31.7 (CH), 28.2 (CH3), 26.0 (CH2), 25.4
(CH2), 24.6 (CH2), 24.5 (CH2), 22.6 (CH2), 14.0 (CH3) ppm; IR (neat):
ν̃max (cm–1) = 3327, 2926, 2854, 1681, 1614, 1521, 1412, 1365; HRMS
(ESI): m/z calculated for C22H41N2O2 [M + H]+ 365.3163, found
365.3150.
Synthesis of N-(tert-Butyl)-1-(2-(4-methoxyphenyl)acetyl)-4-
pentyl-piperidine-2-carboxamide (6l): Another 1.0 mmol aliquot
of 5g (153 mg, 1 equiv., see preparation of 6k) was then used in
the U-3CR together with 4-methoxyphenylacetic acid (199 mg,
1.2 mmol, 1.2 equiv.) and tert-butyl isocyanide (135 μL, 1.2 mmol,
1.2 equiv.) following the general procedure IV. Flash chromatogra-
phy (cyclohexane/EtOAc = 3:1) provided 6l as a white solid (345 mg,
0.85 mmol, 85 %). Two rotamers were present on NMR-timescale in
a 1:0.27 ratio. RF = 0.36 (cyclohexane/EtOAc = 2:1); m.p. 65–66 °C;
1H NMR (CDCl3, 500 MHz): δ 7.17 (d, J = 8.5 Hz, 2.54H), 6.85 (d, J =
8.5 Hz, 2.54H), 5.90 (bs, 1H), 5.26 (bs, 0.27H), 5.16 (d, J = 5.4 Hz, 1H),
4.63 (d, J = 13.2 Hz, 0.27H), 4.44 (d, J = 4.7 Hz, 0.27H), 3.74–3.67 (m,
7.35H), 4.63 (t, J = 13.2 Hz, 0.27H), 2.43 (m, 0.54H), 2.22 (d, J =
12.5 Hz, 1H), 1.78 (m, 1H), 1.64 (m, 2.27H), 1.42 (bs, 0.27H), 1.33–
1.11 (m, 20.59H), 1.04 (m, 1.27H), 0.86 (m, 5.08H) ppm; 13C NMR
(CDCl3, 125 MHz): δ 171.4 (Cq), 171.2 (Cq), 169.9 (Cq), 168.2 (Cq),
158.7 (Cq), 158.5 (Cq), 129.4 (CH), 129.4 (CH), 126.7 (Cq), 126.5 (Cq),
114.6 (CH), 114.3 (CH), 58.4 (CH), 55.3 (CH), 55.3 (CH3), 52.5 (CH3),
51.1 (Cq), 50.9 (Cq), 44.2 (CH2), 40.7 (CH2), 40.2 (CH2), 40.0 (CH2), 36.8
(CH2), 36.5 (CH2), 32.8 (CH2), 32.3 (CH), 32.1 (CH2), 32.0 (CH2), 31.9
(CH2), 31.7 (CH2), 31.6 (CH), 31.3 (CH2), 28.7 (CH3), 28.3 (CH3), 26.1
(CH2), 26.0 (CH2), 22.6 (CH2), 22.6 (CH2), 14.0 (CH3), 14.0 (CH3) ppm;
IR (neat): ν̃max (cm–1) = 3335, 2924, 1680, 1626, 1510, 1450, 1245,
1176, 1034, 640, 576, 530; HRMS (ESI): m/z calculated for C24H39N2O3
[M + H]+ 403.2955, found 403.2968.
Synthesis of Methyl (4-Cyclopentyl-1-pivaloylpiperidine-2-carb-
onyl)-glycinate (6m): The general procedure IV with 0.57 g
(3.0 mmol, 1 equiv.) of 4g gave 0.39 g (2.55 mmol, 85 %.) of 3,4,5,6-
tetrahydro-4-cyclopentylpyridine 5h. An 0.5 mmol aliquot of 5h
(76 mg, 1 equiv.) was then used in the U-3CR together with pivalic
acid (61 mg, 0.6 mmol, 1.2 equiv.) and methyl isocyanoacetate
(55 μL, 0.6 mmol, 1.2 equiv.) following the general procedure IV.
Flash chromatography (cyclohexane/EtOAc = 5:2) provided 6m as a
slowly crystallizing oil (109 mg, 0.31 mmol, 62 %). RF = 0.12 (cyclo-
hexane/EtOAc = 4:1); 1H NMR (CDCl3, 500 MHz): δ 6.68 (bs, 1H), 5.24
(bs, 1H), 4.21 (m, 2H), 3.80 (dd, J = 18.2, 4.2 Hz, 1H), 3.72 (s, 3H),
3.04 (t, J = 13.2 Hz, 1H), 2.37 (d, J = 13.2 Hz, 1H), 1.72–1.68 (m, 3H),
1.59 (m, 3H), 1.53–1.37 (m, 3H), 1.33 (s, 9H), 1.28–1.05 (m, 4H) ppm;
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13C NMR (CDCl3, 125 MHz): δ 178.6 (Cq), 171.7 (Cq), 170.3 (Cq), 52.3
(CH), 46.2 (CH3), 44.5 (CH2), 40.8 (CH2), 38.9 (Cq), 37.6 (CH), 37.6 (CH),
31.0 (CH2), 30.9 (CH2), 30.2 (CH2), 30.1 (CH2), 28.3 (CH3), 25.3 (CH2),
25.2 (CH2) ppm; IR (neat): ν̃max (cm–1) = 3356, 2949, 2868, 1753,
1680, 1618, 1516, 1412, 1366, 1201, 983, 536; HRMS (ESI): m/z calcu-
lated for C19H33N2O4 [M + H]+ 353.2435, found 353.2445.
Synthesis of N-(tert-Butyl)-4-cyclopentyl-1-(2-(4-methoxy-
phenyl)-acetyl)piperidine-2-carboxamide (6n): Another 0.5 mmol
aliquot of 5h (76 mg, 1 equiv., see preparation of 6m) was then
used in the U-3CR together with 4-methoxyphenylacetic acid
(100 mg, 0.6 mmol, 1.2 equiv.) and tert-butyl isocyanide (62 μL,
0.6 mmol, 1.2 equiv.) following the general procedure IV. Column
chromatography (cyclohexane/EtOAc = 3:1) provided 6n as a white
solid (173 mg, 0.43 mmol, 86 %). Two rotamers were present on
NMR-timescale in a 1:0.27 ratio. RF = 0.42 (cyclohexane/EtOAc =
2:1); m.p. 104 °C; 1H NMR (CDCl3, 500 MHz): δ 7.16 (d, J = 8.5 Hz,
2.54H), 7.84 (d, J = 8.5 Hz, 2.54H), 5.92 (bs, 1H), 5.23 (bs, 0.27H), 5.15
(d, J = 4.8 Hz, 1H), 4.61 (d, J = 13.4 Hz, 0.27H), 4.44 (bs, 0.27H), 3.85–
3.66 (m, 7.35H), 2.91 (t, J = 13.2 Hz, 1H), 2.43 (m, 0.54H), 2.26 (d, J =
12.9 Hz, 1H), 1.78–1.31 (m, 12.7H), 1.22 (s, 9.27H), 1.13 (s, 2.43H),
1.11–1.02 (m, 2.27H), 1.00–0.90 (m, 1.27H) ppm; 13C NMR (CDCl3,
125 MHz): δ 171.4 (Cq), 171.1 (Cq), 170.0 (Cq), 168.1 (Cq), 158.6 (Cq),
158.5 (Cq), 129.4 (CH), 129.4 (CH), 126.7 (Cq), 126.5 (Cq), 114.5 (CH),
114.2 (CH), 58.3 (CH), 55.2 (CH), 55.2 (CH3), 52.4 (CH3), 51.1 (Cq), 50.8
(Cq), 46.1 (CH), 45.9 (CH), 44.2 (CH2), 40.7 (CH2), 40.2 (CH2), 39.9
(CH2), 37.9 (CH), 37.3 (CH), 31.8 (CH2), 31.0 (CH2), 30.7 (CH2), 30.3
(CH2), 30.1 (CH2), 30.1 (CH2), 30.0 (CH2), 29.6 (CH2), 28.6 (CH3), 28.3
(CH3), 25.2 (CH2), 25.2 (CH2), 25.2 (CH2), 25.1 (CH2) ppm; IR (neat):
ν̃max (cm–1) = 3337, 2951, 2866, 1678, 1624, 1510, 1450, 1246, 1178,
1036, 910, 729, 646, 526; HRMS (ESI): m/z calculated for C24H37N2O3
[M + H]+ 401.2799, found 401.2813.
Synthesis of 4-Cyclohexyl-N-pentyl-1-pivaloylpiperidine-2-
carbox-amide (6o) : The general procedure IV with 0.61 g
(3.0 mmol, 1 equiv.) of 4h gave 0.46 g (2.76 mmol, 92 %.) of 3,4,5,6-
tetrahydro-4-cyclohexylpyridine 5i. An 0.5 mmol aliquot of 5i
(83 mg, 1 equiv.) was then used in the U-3CR together with pivalic
acid (61 mg, 0.6 mmol, 1.2 equiv.) and pentyl isocyanide (78 μL,
0.6 mmol, 1.2 equiv.) following the general procedure IV. Flash chro-
matography (cyclohexane/EtOAc = 4:1) provided 6o as a white solid
(138 mg, 0.38 mmol, 76 %). RF = 0.31 (cyclohexane/EtOAc = 4:1);
m.p. 108 °C; 1H NMR (CDCl3, 500 MHz): δ 6.19 (bs, 1H), 5.11 (bs, 1H),
4.18 (bs, 1H), 3.25 (m, 1H), 3.11 (m, 1H), 2.89 (m, 1H), 2.29 (d, J =
12.0 Hz, 1H), 1.76–1.59 (m, 1H), 1.42 (m, 2H), 1.27 (s, 9H), 1.26–0.90
(m, 12H), 0.87 (t, J = 7.0 Hz, 3H). 13C NMR (CDCl3, 125 MHz): δ 178.2
(Cq), 171.1 (Cq), 44.4 (CH), 42.5 (CH), 39.1 (CH2), 38.8 (Cq), 37.0 (CH),
29.9 (CH2), 29.6 (CH2), 29.3 (CH2), 29.0 (CH2), 28.8 (CH2), 28.2 (CH3),
26.6 (CH2), 26.4 (CH2), 22.2 (CH2), 13.9 (CH3) ppm; IR (neat): ν̃max
(cm–1) = 3329, 2922, 2851, 1664, 1612, 1522, 1412, 1165, 997, 922,
731, 629, 532; HRMS (ESI): m/z calculated for C22H41N2O2 [M + H]+
365.3163, found 365.3173.
Synthesis of N-(tert-Butyl)-4-cyclohexyl-1-(pent-4-enoyl)piper-
idine-2-carboxamide (6p): Another 0.5 mmol aliquot of 5i (83 mg,
1 equiv., see preparation of 6o) was then used in the U-3CR to-
gether with 4-pentenoic acid (62 μL, 0.6 mmol, 1.2 equiv.) and tert-
butyl isocyanide (62 μL, 0.6 mmol, 1.2 equiv.) following the general
procedure IV. Flash chromatography (cyclohexane/EtOAc = 4:1) pro-
vided 6o as a white solid (155 mg, 0.44 mmol, 89 %). Two rotamers
were present on NMR-timescale in a 1:0.21 ratio. RF = 0.30 (cyclo-
hexane/EtOAc = 4:1); m.p. 140 °C; 1H NMR (CDCl3, 500 MHz): δ 5.96
(bs, 1H), 5.84 (m, 1.21H), 5.70 (bs, 0.21H), 5.14 (d, J = 4.5 Hz, 1H),
5.05 (d, J = 17.1 Hz, 1.21H), 4.99 (d, J = 10.1 Hz, 1.21H), 4.65 (d, J =
12.9 Hz, 0.21H), 4.40 (bs, 0.21H), 3.79 (d, J = 13.3 Hz, 1H), 3.04 (dt,
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J = 13.2, 1.5 Hz, 1H), 2.54–2.31 (m, 5.26H), 2.19 (d, J = 14.1 Hz, 1H),
1.77–1.56 (m, 8.47H), 1.32 (s, 1.89H), 1.28 (s, 9H), 1.1.24–0.81 (m,
9.68H) ppm; 13C NMR (CDCl3, 125 MHz): δ 172.3 (Cq), 171.9 (Cq),
170.3 (Cq), 168.7 (Cq), 137.1 (CH), 137.0 (CH), 115.6 (CH2), 115.4 (CH2),
57.8 (CH), 52.6 (CH), 51.5 (Cq), 50.9 (Cq), 43.7 (CH2), 42.5 (CH), 42.2
(CH), 40.0 (CH2), 37.7 (CH), 36.8 (CH), 32.6 (CH2), 32.5 (CH2), 30.2
(CH2), 29.9 (CH2), 29.6 (CH2), 29.6 (CH2), 29.5 (CH2), 29.2 (CH2), 29.2
(CH2), 29.1 (CH2), 29.0 (CH2), 28.7 (CH3), 28.7 (CH3), 28.2 (CH2), 26.6
(CH2), 26.6 (CH2), 26.5 (CH2), 26.4 (CH2) ppm; IR (neat): ν̃max (cm–1) =
3335, 2922, 2851, 1682, 1627, 1535, 1448, 1425, 1364, 1259, 1224,
999, 910, 730, 644, 403; HRMS (ESI): m/z calculated for C21H37N2O2
[M + H]+ 349.2850, found 349.2857.
Synthesis of 1-Acetyl-N-(tert-butyl)-4-phenylpiperidine-2-
carbox-amide (6q) : The general procedure IV with 0.97 g
(6.0 mmol, 1 equiv.) of commercial 4-phenylpiperidine gave 0.91 g
(5.72 mmol, 95 %.) of 3,4,5,6-tetrahydro-4-phenylpyridine 5j. An
0.35 mmol aliquot of 5j (56 mg, 1 equiv.) was then used in the U-
3CR together with acetic acid (24 μL, 0.42 mmol, 1.2 equiv.) and
tert-butyl isocyanide (48 μL, 0.42 mmol, 1.2 equiv.) following the
general procedure IV. Flash chromatography (EtOAc) provided 6q
as a white solid (101 mg, 0.33 mmol, 95 %). Two rotamers were
present on NMR-timescale in a 1:0.18 ratio. RF = 0.30 (EtOAc); 1H
NMR (CDCl3, 500 MHz): δ 7.34–7.20 (m, 5.90H), 6.07 (bs, 1H), 5.82
(bs, 0.18H), 5.25 (d, J = 5.5 Hz, 1H), 4.81 (d, J = 13.5 Hz, 0.18H), 4.47
(d, J = 5.0 Hz, 0.18H), 3.87 (d, J = 13.5 Hz, 1H), 3.35 (dt, J = 13.0,
2.5 Hz, 1H), 3.25 (tt, J = 12.5, 3.5 Hz, 1H), 2.75 (m, 0.56), 2.37 (m,
1H), 2.22 (s, 3H), 2.18 (s, 0.56H), 1.92 (m, 1.18H), 1.72–1.60 (m, 2.36H),
1.41 (s, 1.62H), 1.36 (s, 9H) ppm. 13C NMR (CDCl3, 125 MHz): δ 170.7
(Cq), 170.3 (Cq), 170.0 (Cq), 168.3 (Cq), 145.2 (Cq), 144.6 (Cq), 128.5
(CH), 128.5 (CH), 126.8 (CH), 126.7 (CH), 126.5 (CH), 126.4 (CH), 58.7
(CH), 52.4 (CH), 51.7 (Cq), 51.0 (Cq), 44.4 (CH2), 39.7 (CH2), 38.4 (CH),
37.6 (CH3), 34.0 (CH2), 33.0 (CH2), 32.6 (CH2), 31.6 (CH2), 28.9 (CH3),
28.8 (CH3), 21.7 (CH3), 21.7 (CH3) ppm. IR (neat): ν̃max (cm–1) = 3317,
2966, 1678, 1627, 1533, 1421, 1364, 1256, 1225, 729, 698; HRMS
(ESI): m/z calculated for C18H26N2NaO2 [M + Na]+ 325.1886, found
325.1901. A single crystal suitable for X-ray diffraction was grown
from a dichloromethane/pentane mixture. CCDC 1910686 (for com-
pound 6q) contains the supplementary crystallographic data for
this paper. These data can be obtained free of charge from The
Cambridge Crystallographic Data Centre.
Synthesis of 1-Acetyl-N-cyclohexyl-4-phenylpiperidine-2-
carbox-amide (6r): Another 0.35 mmol aliquot of 5j (56 mg,
1 equiv., see preparation of 6q) was then used in the U-3CR to-
gether with acetic acid (24 μL, 0.42 mmol, 1.2 equiv.) and cyclohexyl
isocyanide (52 μL, 0.42 mmol, 1.2 equiv.) following the general pro-
cedure IV. Flash chromatography (EtOAc) provided 6r as a white
solid (103 mg, 0.31 mmol, 90 %); Two rotamers were present on
NMR-timescale in a 1:0.24 ratio. RF = 0.40 (EtOAc); 1H NMR (CDCl3,
500 MHz): δ 7.34–7.18 (m, 6.20H), 6.11 (d, J = 7.5 Hz, 1H), 6.05 (d,
J = 8.5 Hz, 0.24H), 5.29 (d, J = 5.5 Hz, 1H), 4.78 (d, J = 13.5 Hz,
0.24H), 4.51 (d, J = 5.5 Hz, 0.24H), 3.85 (d, J = 13.5 Hz, 1H), 3.76 (m,
1.24H), 3.33 (dt, J = 13.0, 2.5 Hz, 1H), 3.20 (tt, J = 12.5, 3.5 Hz, 1H),
2.72 (m, 0.72), 2.38 (m, 1H), 2.20 (s, 3H), 2.16 (s, 0.72H), 1.97–1.80
(m, 3.72H), 1.77–1.56 (m, 6.2H), 1.42–1.30 (m, 2.48H), 1.23–1.10 (m,
3.72H) ppm. 13C NMR (CDCl3, 125 MHz): δ 170.7 (Cq), 170.3 (Cq),
169.7 (Cq), 167.9 (Cq), 145.1 (Cq), 144.5 (Cq), 128.5 (CH), 128.5 (CH),
126.7 (CH), 126.7 (CH), 126.5 (CH), 126.4 (CH), 58.3 (CH), 51.9 (CH),
48.7 (CH), 48.0 (CH), 44.4 (CH2), 39.6 (CH2), 38.4 (CH), 37.7 (CH), 33.1
(CH2), 33.0 (CH2), 32.8 (CH2), 32.5 (CH2), 25.4 (CH2), 25.3 (CH2), 24.9
(CH2), 24.7 (CH2), 21.8 (CH3), 21.7 (CH3) ppm. IR (neat): ν̃max (cm–1) =
3300, 2930, 2854, 1631, 1527, 1421, 730, 633, 534, 496; HRMS (ESI):
m/z calculated for C20H28N2NaO2 [M + Na]+ 351.2043, found
351.2058.
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Synthesis of Argatroban (3)
Nω,Nω′-Bis((benzyloxy)carbonyl)-N2-((3-methylquinoliN-8-yl)-
sulfon-yl)-L-arginine (8b): TFA (65 mL) was added to a solution of
21 (Boc-Arg(Cbz)2-OH; 2.5 g, 4.61 mmol, 1 equiv.) in CH2Cl2 (65 mL)
at 0 °C. The reaction mixture was stirred for 1 h at this temperature
and then concentrated under reduced pressure. The resulting resi-
due was co-evaporated two times with toluene to furnish an off-
white foamy solid. The residue was redissolved into a 2:1 mixture
of THF and H2O (120 mL) and DIPEA (4.00 mL, 23.0 mmol, 5 equiv.)
was added. Then, the resulting solution was cooled to 0 °C and 22
(3-methylquinoline-8-sulfonyl chloride; 1.34 g, 5.53 mmol,
1.2 equiv.) was added portion wise. After complete addition, the
reaction mixture was warmed to room temperature and stirred for
16 h. Next, EtOAc was added (50 mL) and the layers were separated.
The water layer was extracted with ethyl acetate (2 × 50 mL) and
the combined layers were washed with saturated NH4Cl(aq.) and
Brine, dried with Na2SO4, filtered and concentrated under reduced
pressure. The residue was purified by flash chromatography (cyclo-
hexane/EtOAc = 1:4) to obtain 8b as a white foamy solid (2.94 g,
4.54 mmol, 98 %). RF = 0.20 (cyclohexane/EtOAc = 1:4); m.p. 160 °C;
[α]D20 + 80° (c = 1.00, CHCl3); 1H NMR (CDCl3, 500 MHz): δ 9.36 (bs,
1H), 9.27 (bs, 1H), 8.78 (s, 1H), 8.26 (d, J = 7.0 Hz, 1H), 7.92 (s, 1H),
7.88 (d, J = 8.0 Hz, 1H), 7.48 (t, J = 7.5 Hz, 1H), 7.42–7.35 (m, 5H),
7.26–7.14 (m, 5H), 5.23 (s, 2H), 4.94 (d, J = 12.5 Hz, 1H), 4.81 (d, J =
12.5 Hz, 1H), 4.24 (bs, 1H), 3.91 (m, 2H), 2.46 (s, 3H), 1.89–1.61 (m,
4H) ppm; 13C NMR (CDCl3, 125 MHz): δ 174.1 (Cq), 163.3 (Cq), 160.5
(Cq), 155.7 (Cq), 153.0 (CH), 141.1 (Cq), 136.5 (Cq), 136.0 (Cq), 125.6
(CH), 134.5 (Cq), 132.9 (CH), 132.1 (Cq), 129.9 (CH), 128.8 (CH), 128.6
(Cq), 128.4 (CH), 128.3 (CH), 127.7 (CH), 127.5 (CH), 125.3 (CH), 69.0
(CH2), 66.7 (CH2), 55.9 (CH), 29.2 (CH2), 24.3 (CH2), 18.6 (CH3) ppm;
IR (neat): ν̃max (cm–1) = 2986, 2363, 1717, 1607, 1508, 1240, 1161,
1095, 696, 584; HRMS (ESI): m/z calculated for C23H34N5O8S [M +
H]+ 648.2123, found 648.2121.
1-(Nω,Nω′-Bis(1-(benzyloxy)carbonyl)-N2-((3-methylquinolin-8-
yl)-sulfonyl)-L-arginyl)-N-(6-bromopyridin-2-yl)-4-methylpiper-
idine-2-carboxamide (9b): Tetrahydro-4-methyl pyridine 5a
(146 mg, 1.50 mmol, 1.0 equiv.), obtained quantitatively from com-
mercial 4-methyl piperidine using the general procedure IV, was
dissolved in TFE (10 mL). Then, amino acid 8b (1.46 g, 2.25 mmol,
1.5 equiv.) and 2-bromo-6-isocyanopyridine[30] (7; 329 mg,
1.80 mmol, 1.20 equiv.) were added sequentially. After 48 h the
mixture was concentrated in vacuo and purified using flash chroma-
tography (cyclohexane/EtOAc = 4:1) to yield an off-white foam
(902 mg, 0.97 mmol, 65 %). The product is a 1:1 mixture of dia-
stereoisomers. NMR-analysis displays rotamers of which the major
signals are reported 1H NMR (CDCl3, 500 MHz): δ 9.45 (bs, 2H), 9.28
(bs, 2H), 8.92 (s, 1H), 8.82 (s, 2H), 8.33 (d, J = 7.0 Hz, 1H), 8.24 (d, J =
7.5 Hz, 1H), 8.03–7.90 (m, 4H), 7.78 (s, 1H), 7.74 (s, 1H), 7.70 (d, J =
7.0 Hz, 1H), 7.56 (t, J = 8.0 Hz, 1H), 7.52 (t, J = 8.0 Hz, 1H), 7.49–7.25
(m, 21H), 7.14 (m, 2H), 5.30–5.04 (m, 8H), 4.79 (d, J = 5.5 Hz, 1H),
4.72 (m, 1H), 4.50 (m, 1H), 4.46 (d, J = 5.5 Hz, 1H), 4.08–3.93 (m, 4H),
3.70 (d, J = 13.5 Hz, 1H), 3.65 (d, J = 13.5 Hz, 1H), 3.04 (dt, J = 13.0,
2.0 Hz, 1H), 2.95 (dt, J = 13.0, 2.0 Hz, 1H), 2.95 (s, 3H), 2.40 (s, 3H),
1.95 (d, J = 14.0 Hz, 1H), 1.89–1.50 (m, 12H), 1.40 (d, J = 12.5 Hz,
1H), 0.92 (m, 2H), 0.82 (d, J = 6.5 Hz, 3H), 0.80 (d, J = 6.5 Hz, 3H),
0.63 (dq, J = 12.5, 4.0 Hz, 1H), 0.37 (dt, J = 13.0, 6.0 Hz, 1H) ppm;
13C NMR (CDCl3, 125 MHz): δ 171.4 (Cq), 171.1 (Cq), 168.8 (Cq), 168.7
(Cq), 163.8 (Cq), 163.7 (Cq), 160.5 (Cq), 160.5 (Cq), 155.8 (Cq), 155.8
(Cq), 153.3 (CH), 152.7 (CH), 150.8 (Cq), 150.7 (Cq), 141.5 (Cq), 141.4
(Cq), 140.3 (CH), 140.1 (CH), 139.3 (Cq), 139.2 (Cq), 136.8 (Cq), 136.8
(Cq), 136.8 (Cq), 135.2 (CH), 135.0 (CH), 134.7 (Cq), 134.6 (Cq), 132.7
(CH), 132.6 (CH), 132.2 (CH), 131.7 (CH), 128.8 (CH), 128.8 (CH), 128.8
(CH), 128.8 (CH), 128.7 (CH), 128.7 (CH), 128.5 (CH), 128.5 (Cq), 128.4
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(CH), 128.4 (Cq), 128.4 (CH), 128.3 (CH), 128.1 (CH), 127.9 (CH), 127.8
(CH), 127.7 (CH), 125.3 (CH), 125.1 (CH), 123.7 (CH), 123.6 (CH), 112.4
(CH), 112.0 (CH), 69.0 (CH2), 68.9 (CH2), 66.9 (CH2), 66.9 (CH2), 54.1
(CH), 53.3 (CH), 53.0 (CH), 52.8 (CH), 44.0 (CH2), 43.9 (CH2), 43.6 (CH2),
43.3 (CH2), 33.6 (CH2), 33.5 (CH2), 33.1 (CH2), 33.0 (CH2), 30.8 (CH2),
30.4 (CH2), 26.5 (CH), 26.3 (CH), 24.7 (CH2), 24.5 (CH2), 21.7 (CH3),
21.6 (CH3), 18.8 (CH3), 18.7 (CH3) ppm; IR (neat): ν̃max (cm–1) = 1717,
1604, 1564, 1508, 1431, 1384, 1223, 1155, 1090, 696, 581; HRMS
(ESI): m/z calculated for C44H48BrN8O8S [M + H]+ 927.2494, found
927.2510.
4-Methyl-1-(((3-Methyl-1,2,3,4-tetrahydroquinolin-8-yl)sulf-
onyl)-L-arginyl)piperidine-2-carboxylic Acid (Argatroban, 3): U-
3CR product 9b (186 mg, 0.20 mmol, 1.0 equiv.) was dissolved into
ethanol (2 mL) and aqueous NaOH (2 M, 1.0 mL, 2.0 mmol,
10 equiv.) was added dropwise to the solution. The resulting mix-
ture was heated to reflux and stirred for 1 hour. The mixture was
cooled to room temperature and CH2Cl2 (3 mL) was added. The
water layer was acidified to pH 2 with an aqueous HCl solution
(2 M) and extracted with CH2Cl2 (3 ×). The collected organic frac-
tions were dried with Na2SO4, filtered and concentrated under re-
duced pressure. The crude product was further purified using flash
chromatography (EtOAc/iPrOH/H2O = 5:2:0.25) to yield an off-white
powder (120 mg, 0.188 mmol, 94 %). The resulting product is a
mixture of two diastereoisomers of the hydrolyzed (2R,4R)-1-(Nω′-
((benzyloxy)carbonyl)-N2-((3-methylquinolin-8-yl)sulfonyl)-l-ar-
ginyl)-4-methylpiperidine-2-carboxylic acid as well as the derivative
with the second Cbz-group partially cleaved. RF = 0.75 (EtOAc/iP-
rOH/H2O = 4:2:1); 1H NMR (CDCl3, 500 MHz): δ 8.93 (s, 1H), 8.31 (d,
J = 6.5 Hz, 1H), 8.15 (s, 1H), 8.01 (d, J = 8.0 Hz, 1H), 7.63 (t, J =
7.5 Hz, 1H), 7.45–7.36 (m, 5H), 5.22 (s, 1H), 4.44–4.36 (m, 2H), 3.85
(d, J = 12.5 Hz, 1H), 3.38–3.12 (m, 3H), 2.58 (s, 1H), 2.10 (m, 1H),
1.78–1.45 (m, 6H), 0.88 (m, 1H), 0.79 (d, J = 6.0 Hz, 3H), 0.67 (m, 1H)
ppm. HRMS (ESI): m/z calculated for C31H44N6O7S [M + H]+ 639.2595,
found 639.2581. Then, 32 mg of this material (0.05 mmol, 1.0 equiv.)
was dissolved in a 1:1 mixture of ethanol and acetic acid (5 mL)
and Pd/C (10 w/w %, 6 mg, 0.005 mmol, 0.1 equiv.) was added. The
reaction flask was exposed to an atmospheric pressure of H2 and
stirred for 16 h at r.t. Then, the suspension was filtered through
Celite, concentrated in vacuo and purified by flash chromatography
(CH2Cl2/MeOH = 80:20) to yield the title compound as a white solid
(22 mg, 0.044 mmol, 88 %). The product is available as a 1:1 mixture
of diastereoisomers.
The reaction was repeated with the single diastereoisomer obtained
by SFC separation on 2.5 mg scale. Argatroban (3, 2 mg) was ob-
tained as a mixture of two epimers at the quinoline ring in a 36:64
ratio. 1H NMR (MeOD, 500 MHz): δ 7.44 (d, J = 7.5 Hz, 1H), 7.10 (d,
J = 7.5 Hz, 1H), 6.55 (t, J = 6.5 Hz, 1H), 4.63 (bs, 2H), 4.13 (m, 2H),
4.00 (m, 1H), 3.43 (m, 1H), 3.22–2.68 (m, 5H), 2.43 (m, 1H), 2.15 (m,
1H), 1.99 (m, 1H), 1.69 (m, 3H), 1.48 (m, 3H), 1.07 (d, J = 6.5 Hz, 3H),
0.70 (m, 1H), 0.88 (d, J = 5.5 Hz, 3H), 0.65 (m, 1H) ppm; 13C NMR
(MeOD, 125 MHz): δ 177.4 (Cq), 171.4 (Cq), 158.6 (Cq), 144.2 (Cq),
135.3 (CH), 128.9 (CH), 124.5 (Cq), 119.6 (Cq), 115.7 (CH), 59.6 (CH),
53.1 (CH), 49.1 (CH2), 41.5 (CH2), 41.0 (CH2), 37.5 (CH2), 37.1 (CH2),
34.2 (CH2), 30.5 (CH2), 28.8 (CH), 27.0 (CH), 25.0 (CH2), 22.3 (CH3),
19.0 (CH3) ppm; HRMS (ESI): m/z calculated for C23H37N6O5S [M +
H]+ 509.2541, found 509.2525, which is in agreement with spectro-
scopic data of 3 from literature.[41–43]
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